Navigation Links
Nanotechnology Could Revolutionize Cardiac Treatment

Scientists have developed nanomolcecules called ‘nanolipoblockers’ that guard against bad cholesterol. The molecules are designed in such a way that they offer a local therapeutic effect,// aimed at reducing the recurrence of blocked blood vessels in cardiac patients. These nanoengineered molecules, which represent the first line of defense against harmful cholesterol could soon join the fight against heart disease, perhaps even help prevent it in high-risk individuals.

In a paper scheduled for publication June 12 in the American Chemical Society's journal Biomacromolecules and now appearing on that journal's Web site, Rutgers researchers propose a way to combat clogged arteries by attacking how bad cholesterol triggers inflammation and causes plaque buildup at specific blood vessel sites. Their approach contrasts with today's statin drug therapy, which aims to reduce the amount of low-density lipids, or LDLs (‘bad’ cholesterol), throughout the body.

In an ironic twist, the Rutgers approach aims to thwart a biological process that is typically beneficial and necessary. Prabhas Mogue, the principal investigator and associate professor of biomedical engineering and chemical and biochemical engineering at Rutgers, said that vascular plaque and inflammation develop when certain forms of LDL are attacked by white blood cells that scavenge cellular debris and disease agents. ‘While these scavengers, called macrophages, perform an essential role in keeping organisms healthy, their interaction with highly oxidized LDL molecules has quite the opposite effect,’ he said.

Mogue explains that macrophages accumulate large amounts of oxidized LDL and secrete chemicals that can damage the neighboring tissues and, ultimately, become fatty foam cells. The researchers' approach, therefore, is to create clusters of nanoengineered molecules that target specific receptor molecules on cell membranes and block these oxidized LDLs from attaching to macrop hages.

Mogue is working with Kathryn Uhrich, Rutgers professor of chemistry and chemical biology, who is an expert at synthesizing biologically useful molecules at the nanoscale – anywhere from 10 to 100 nanometers long. The research team, which also includes graduate student Evangelia Chnari and synthetic chemists Lu Tian and Jinzhong Wang, has designed a family of nanolipoblockers, or NLBs, which compete with oxidized LDL for a macrophage's attention. The NLBs bind to receptor sites on macrophages, cutting the accumulation of oxidized LDL by as much as 75 percent.

The NLB particles are made of several engineered organic strands or chains whose ends cluster around a central point, creating a structure known as a micelle. Uhrich synthesized molecule chains with several different characteristics, such as attracting or repelling water or having a positive or negative charge. When the chains assembled into micelles, Mogue tested them for how well they blocked LDL uptake.

‘We're employing the tools of nanotechnology – specifically tailoring the structure of the molecule, changing groups on the ends of the chains and closely analyzing which forms of the particles bind to the different macrophage receptors,’ Uhrich said. ‘The significant finding of our study is that the nanoscale organization matters tremendously for blockage of oxidized LDL, which opens new avenues for more specific targeting of receptors.’

Mogue said that if this method proves feasible in living organisms, it could convey treatment to the site of the problem, rather than a systemic approach. ‘While statins are a great stride in preventing cardiovascular disease, they are not suitable for everyone,’ Mogue said. ‘Our approach also has potential to topically address the recurrence of inflammation and blockage at stent surgery sites, something that systemically active drugs have not been shown to consistently do.’

Research to test the performance of NLBs in living organisms is now under way.

Soure: Eurekalert
'"/>




Related medicine news :

1. CoQ10 bioavailability increased by Nanotechnology
2. Nanotechnology Revolution To Be Spearheaded By European Union
3. RNA Nanotechnology To Rescue Cancer Patients In Future
4. Scientists Consider About New Technology Called Nanotechnology
5. Potential Benefits Of New Nanotechnology
6. Nanotechnology Promises Huge Medical Benefits
7. Nanotechnology at its best: Nanomotors And Mechanical Nanoswitches
8. Anti-Sense Drugs and Nanotechnology Offer New Hope In Cancer Fight
9. Nanotechnology – to detect and treat ovarian cance
10. Nanotechnology Used For Detecting Viruses
11. India, China Trying to Fight Disease With Nanotechnology
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/20/2017)... ... ... Are you an adult with gluten intolerance or Celiac disease living with ... participating in a research study that focuses on family interactions when dealing with dietary ... aspects of adults who have gluten sensitivities who cohabitate with other adults who may ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... is the first organization with pending recognition status from the Centers for Disease ... via group telehealth classes and live video conferencing. , The DPP resulted ...
(Date:8/19/2017)... ... August 19, 2017 , ... Physician Partners of ... location as an interventional pain management physician. He brings a wealth of pain ... migraine headaches, and significant experience in spinal cord stimulation for chronic pain. , ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... specialized asset-light logistics provider of complex transport solutions for mission-critical and non-discretionary ... Unitrans International Corporation, a division of Roadrunner Transportation Systems, Inc. (NYSE: RRTS). ...
(Date:8/18/2017)... ... ... The Dawn Johnson Insurance Group, a Missouri-based insurance and financial planning firm ... for efforts to educate the local population on cancer realities while attracting donations to ... , Each day in America, roughly 4,600 new cases of cancer are diagnosed and ...
Breaking Medicine News(10 mins):
(Date:8/10/2017)... 2017  Physical Rehabilitation Network (PRN), acquired the long-standing outpatient ... Colorado . The reputable clinic will continue to be ... with his staff of four clinicians. Lipkin received his doctorate ... over 10 years of experience with a strong background in ... marks the 10th PRN clinic in and around the ...
(Date:8/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... Board of Directors has approved the payment of a quarterly ... The cash dividend of ... 27, 2017 to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
(Date:8/4/2017)... The search for test results that can ... has long been the goal of healthcare providers and ... the largest meeting of lab professionals and IVD firms ... firm Kalorama Information.  The firm said scores of companies ... supplies and software were at the American Association for ...
Breaking Medicine Technology: